Corrections to “Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines”
Year: 2018
Type: erratum
Abstract: Ann Oncol 2018; 29: iv96–iv110 (doi:10.1093/annonc/mdx758) The following corrections have been made: In “Table 2. Managing anaemia in patients with MDS” In the last sentence, the word: patient has been replaced with: patients In “Table 4. Approved ESAs and i.v. iron compounds and their approved dosing in patients with solid tumours and haematological malignanciesa,b” For iron isomaltoside, maximum infusion dose, a new footnote ‘e’ has been added: eThe authors suggest a dose up to 1000 mg, while drug labels might allow more. For iron isomaltoside, minimum infusion time: 60 min Has been replaced with: 15 minf For iron isomaltoside, minimum infusion time, a new footnote ‘f’ has been added: fIf dose is up to 1000 mg; if dose exceeds 1000 mg iron, more than 30 min is recommended, as per label. In Figure 2: “Management of chemotherapy-induced anaemia in patients with very low to intermediate-risk MDS” The title has been replaced with: Management of anaemia in patients with very low to intermediate-risk MDS Under the section “Conclusions” MDS patients with low to intermediate-1 risk (IPSS) or very low to intermediate risk (revised; IPSS-R) disease and symptomatic anaemia should be considered for ESA therapy, despite the fact that ESAs are currently not EMA-approved for use in patients with MDS [I, A]. Has been replaced with: MDS patients with low to intermediate-1 risk (IPSS) or very low to intermediate risk (revised; IPSS-R) disease and symptomatic anaemia should be considered for ESA therapy, despite the fact that not all ESAs are currently EMA-approved for use in patients with MDS [I, A]. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice GuidelinesAnnals of OncologyVol. 29PreviewAnaemia and iron deficiency (ID) are frequent complications in patients with solid tumours or haematological malignancies, particularly in patients treated with chemotherapeutic agents [1–3]. Frequently, anaemia is associated with fatigue, impaired physical function and reduced quality of life (QoL) [4–7]. Consequences of anaemia may include impaired response to cancer treatment and reduced overall survival (OS), even though a causal direct relationship has not yet been established [8, 9]. Full-Text PDF Open Archive
Source: Annals of Oncology
Authors: M. Aapro, Y. Beguin, C. Bokemeyer, M. Dicato, P. Gascón, J. Glaspy, A. Hofmann, H. Link, T. Littlewood, H. Ludwig, A. Österborg, P. Pronzato, V. Santini, D. Schrijvers, R. Stauder, K. Jordan, J. Herrstedt
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2999423598